Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?

Summary

The article discusses potential new KEYTRUDA approvals for breast and bladder cancer indications that could impact Merck's commercial narrative post-exclusivity. Specific approval outcomes, dates, and clinical trial data are not provided in the headline.